LU90224I2 - Candesartan cilexetil ou un sel pharmaceutiquement acceptable de celui-ci (ATACAND ) - Google Patents

Candesartan cilexetil ou un sel pharmaceutiquement acceptable de celui-ci (ATACAND )

Info

Publication number
LU90224I2
LU90224I2 LU90224C LU90224C LU90224I2 LU 90224 I2 LU90224 I2 LU 90224I2 LU 90224 C LU90224 C LU 90224C LU 90224 C LU90224 C LU 90224C LU 90224 I2 LU90224 I2 LU 90224I2
Authority
LU
Luxembourg
Prior art keywords
anion
atacand
substd
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
LU90224C
Other languages
English (en)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27526589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90224(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of LU90224I2 publication Critical patent/LU90224I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU90224C 1990-04-27 1998-03-11 Candesartan cilexetil ou un sel pharmaceutiquement acceptable de celui-ci (ATACAND ) LU90224I2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP11314890 1990-04-27
JP14194290 1990-05-30
JP20866290 1990-08-06
JP26457990 1990-10-01
JP41367990 1990-12-24

Publications (1)

Publication Number Publication Date
LU90224I2 true LU90224I2 (fr) 1998-05-11

Family

ID=27526589

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90224C LU90224I2 (fr) 1990-04-27 1998-03-11 Candesartan cilexetil ou un sel pharmaceutiquement acceptable de celui-ci (ATACAND )

Country Status (22)

Country Link
US (4) US5196444A (fr)
EP (2) EP0459136B1 (fr)
JP (2) JP2514282B2 (fr)
KR (1) KR100200541B1 (fr)
CN (2) CN1048486C (fr)
AT (2) ATE146779T1 (fr)
CA (2) CA2040955C (fr)
CY (1) CY2150B1 (fr)
DE (3) DE19875004I2 (fr)
DK (2) DK0459136T3 (fr)
ES (2) ES2095266T3 (fr)
FI (2) FI108434B (fr)
GR (1) GR3022172T3 (fr)
HK (1) HK1000803A1 (fr)
HU (2) HU213266B (fr)
IE (1) IE911317A1 (fr)
LU (1) LU90224I2 (fr)
LV (1) LV10258B (fr)
NL (1) NL970044I2 (fr)
NO (3) NO300923B1 (fr)
NZ (1) NZ237949A (fr)
PT (1) PT97451B (fr)

Families Citing this family (231)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223499A (en) * 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
DE4036706A1 (de) * 1990-11-17 1992-05-21 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
GB9027198D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
FR2673427B1 (fr) * 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
TW274551B (fr) * 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
GB9201789D0 (en) * 1992-01-28 1992-03-11 Fujisawa Pharmaceutical Co Heterocyclic derivatives
US5354759A (en) * 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
TW284688B (fr) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
JP2682353B2 (ja) * 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
DE4203872A1 (de) * 1992-02-11 1993-08-12 Thomae Gmbh Dr K Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1993018030A1 (fr) * 1992-03-03 1993-09-16 Fujisawa Pharmaceutical Co., Ltd. Derives de benzimidazole antagonistes de l'angiotensine ii
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
DK154092D0 (da) * 1992-12-23 1992-12-23 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases
CA2115985A1 (fr) * 1993-02-25 1994-08-26 Kohei Nishikawa Inhibiteur de l'hypertrophie vasculaire
JP2003306432A (ja) * 1993-04-22 2003-10-28 Takeda Chem Ind Ltd 腎疾患の予防または治療剤
JP3810020B2 (ja) * 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (fr) * 1993-06-07 2005-04-26 Yoshiyuki Inada Composition pharmaceutique pour le traitement des affections mediees par l'angiotensine ii
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
US5391566A (en) * 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
ZA945190B (en) * 1993-07-30 1995-02-24 Kotobuki Seiyaku Co Ltd Carboxymethylidenecycloheptimidazole derivatives method or manufacturing the same and therapeutic agents containing these compounds
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
DK0668272T3 (da) * 1994-01-28 2000-09-18 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af tetrazolylforbindelser
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU684916B2 (en) * 1994-03-16 1998-01-08 Sankyo Company Limited Ocular tension depressant
AU677702B2 (en) * 1994-10-13 1997-05-01 Takeda Pharmaceutical Company Limited A prophylactic or therapeutic drug for renal diseases
SE9501881D0 (sv) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII-receptor antagonists
SE9502219D0 (sv) * 1995-06-19 1995-06-19 Astra Ab Novel medical use
JPH11513395A (ja) * 1995-10-06 1999-11-16 ノバルティス・アクチエンゲゼルシャフト 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
EP0882718B1 (fr) * 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Derives du benzimidazole
ATE230263T1 (de) 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
NZ330774A (en) * 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
HU225415B1 (en) * 1996-07-15 2006-11-28 Sankyo Co Medicinal compositions comprising cs-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma
US5771604A (en) * 1997-04-07 1998-06-30 Maytag Corporation Clothes dryer air inlet arrangement
US6177587B1 (en) 1997-05-26 2001-01-23 Takeda Chemical Industries, Ltd. Production method of aminobenzene compound
TW453999B (en) 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
ES2238770T5 (es) 1997-10-17 2012-01-17 Ark Therapeutics Limited Utilización de inhibidores del sistema renina-angiotensina para el tratamiento de la hipoxia o de la disminución de la función metabólica.
EP1069113A1 (fr) * 1998-02-23 2001-01-17 Kureha Chemical Industry Co., Ltd. Derive du benzimidazole
DE19820151A1 (de) * 1998-05-06 1999-11-11 Hexal Ag Transdermales therapeutisches System zur Anwendung von Candesartan
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CN1187337C (zh) 1998-07-15 2005-02-02 帝人株式会社 硫代苯并咪唑衍生物
NZ511938A (en) 1998-12-23 2004-02-27 Novartis Ag Use of AT-1 receptor antagonist or treating diseases associated with an increase of AT-1 receptor
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
ATE487491T1 (de) * 1999-02-19 2010-11-15 Takeda Pharmaceutical Präparationen zur perkutanen aufnahme von zusammnesetzungen die einen angiotensin-ii- rezeptorantagonismus aufweisen
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
IL146971A0 (en) * 1999-06-10 2002-08-14 Warner Lambert Co Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
JP2001089393A (ja) 1999-07-21 2001-04-03 Takeda Chem Ind Ltd 脳血管障害の再発予防剤および脳血管障害の後遺症の改善・進展抑制剤
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
AU3408801A (en) 2000-02-18 2001-08-27 Takeda Chemical Industries Ltd Tnf-alpha inhibitors
SE0002353D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New use
EP1309596B1 (fr) * 2000-08-11 2008-02-06 Boehringer Ingelheim Pharmaceuticals Inc. Composes heterocycliques utiles en tant qu'inhibiteurs de tyrosine kinases
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
EP1314425A4 (fr) * 2000-08-30 2004-06-02 Sankyo Co Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
AU2002210925A1 (en) * 2000-10-25 2002-05-06 Takeda Chemical Industries Ltd. Preventives/remedies for portal hypertension
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2002043709A1 (fr) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
WO2003014112A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Cristal et procede de fabrication correspondant
EP1421953A4 (fr) * 2001-08-28 2004-09-15 Sankyo Co Compositions medicinales contenant un antagoniste du recepteur d'angiotensine ii
US7107198B2 (en) * 2001-11-02 2006-09-12 Sun Microsystems, Inc. Automatic generation of reduced-size circuit models including inductive interaction
EP1444988A4 (fr) 2001-11-13 2007-04-25 Takeda Pharmaceutical Agents anticancer
DE10205335A1 (de) * 2002-02-07 2003-08-21 Bdd Group Holding Ag Zug Deuterierte biphenylsubstituierte Benzimidazole sowie diese Verbindungen enthaltende Arzneimittel
EP1482896A4 (fr) * 2002-03-01 2005-11-23 Merck & Co Inc Aminoalkylphosphonates et composes associes utilises en tant qu'agonistes du recepteur edg
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
EA200500234A1 (ru) 2002-08-19 2005-08-25 Пфайзер Продактс Инк. Комбинированная терапия гиперпролиферативных болезней
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
DE602004013405T2 (de) * 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
WO2004085426A1 (fr) * 2003-03-27 2004-10-07 Hetero Drugs Limited Nouvelles formes cristallines de candesartan cilexetil
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
WO2004094391A2 (fr) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Procede de preparation du valsartan et de ses intermediaires
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
ES2348300T3 (es) * 2003-08-27 2010-12-02 Zentiva, K.S. Procedimiento para eliminar el grupo protector trifenilmetano.
WO2005030202A1 (fr) * 2003-09-26 2005-04-07 Novartis Ag Utilisation des antagonistes du recepteur de l'angiotensine ii pour le traitement de troubles cerebrovasculaires
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
ES2284068T3 (es) * 2003-10-16 2007-11-01 Teva Pharmaceutical Industries Limited Preparacion de candesartan cilexetilo.
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
EP2428516A1 (fr) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
WO2005051928A1 (fr) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Procede de preparation de composes de tetrazolyle
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2005206603A (ja) * 2004-01-21 2005-08-04 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチルの調製
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
CA2555294A1 (fr) * 2004-02-11 2005-08-25 Marina Yu Etinger Polymorphes de candesartan cilexetil
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
RU2426532C2 (ru) 2004-03-17 2011-08-20 Новартис Аг Применение органических соединений
CA2561700A1 (fr) * 2004-04-16 2005-12-15 Santarus, Inc. Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique
MXPA06012702A (es) * 2004-05-05 2007-04-02 Teva Pharma Preparacion de candesartan cilexetil de alta pureza.
JP2009185060A (ja) * 2004-05-19 2009-08-20 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチル多形体
JP2005330277A (ja) * 2004-05-19 2005-12-02 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチル多形体
US7588779B2 (en) * 2004-05-28 2009-09-15 Andrx Labs, Llc Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
WO2005123720A1 (fr) * 2004-06-18 2005-12-29 Ranbaxy Laboratories Limited Fines particules d'un antagoniste de l'angiotensine ii a base de candesartan cilexetil et leur procede de production
WO2006023864A1 (fr) 2004-08-23 2006-03-02 Wyeth Acides pyrrolo-naphtyliques en tant qu’inhibiteurs du pai-1
WO2006023866A2 (fr) 2004-08-23 2006-03-02 Wyeth Acides thiazolo-naphthyliques
MX2007002178A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de oxazolo-naftilo como moduladores del inhibidor del activador de plasminogeno tipo 1 (pai-1) util en el tratamiento de trombosis y enfermedades cardiovasculares.
RU2407523C2 (ru) 2004-10-08 2010-12-27 Новартис Аг Применение ингибиторов ренина для профилактики или лечения диастолической дисфункции или диастолической сердечной недостаточности
US7923573B2 (en) 2004-10-27 2011-04-12 Daiichi Sankyo Company, Limited Benzene compound having 2 or more substituents
EP1806137A4 (fr) * 2004-10-29 2011-03-30 Kowa Co Agent thérapeutique contre les maladies glomérulaires
EP1655298A1 (fr) * 2004-11-03 2006-05-10 LEK Pharmaceuticals d.d. Formes polymorphes du candesartan cilexetil
WO2006050922A1 (fr) 2004-11-11 2006-05-18 Lek Pharmaceuticals D.D. Procede pour la synthese de tetrazoles
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
DE102004060699A1 (de) * 2004-12-16 2006-06-22 Ratiopharm Gmbh Verfahren zur Herstellung von Candesartan
ES2308591T3 (es) * 2004-12-22 2008-12-01 Algry Quimica, S.L Intermedios para la preparacion de antagonistas de los receptores de la angiotensina ii.
CN101132770A (zh) * 2005-01-06 2008-02-27 伊兰制药国际有限公司 纳米微粒坎地沙坦制剂
KR20070088783A (ko) * 2005-01-14 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 조 칸데사르탄 실렉세틸의 제조
JP2008528456A (ja) * 2005-01-26 2008-07-31 レツク・フアーマシユーテイカルズ・デー・デー 親油性結晶性物質としてカンデサルタンシレキセチルを含む新規な医薬組成物
AR055755A1 (es) * 2005-03-30 2007-09-05 Takeda Pharmaceutical Derivado de bencimidazol, procesos de obtencion, composiciones farmaceuticas y usos.
TW200719896A (en) * 2005-04-18 2007-06-01 Astrazeneca Ab Combination product
CN100400536C (zh) * 2005-04-30 2008-07-09 重庆圣华曦药业有限公司 坎地沙坦酯c-型晶体的制备方法
KR100978592B1 (ko) * 2005-05-10 2010-08-27 테바 파마슈티컬 인더스트리즈 리미티드 안정한 미세 분말 칸데사탄 실렉세틸 및 이것의 제조 방법
WO2007074399A2 (fr) 2005-06-06 2007-07-05 Medichem, S.A. Procede de preparation de composes tetrazolyle
ES2264641B1 (es) * 2005-06-17 2008-03-01 Quimica Sintetica, S.A. Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
CN101263136A (zh) 2005-07-13 2008-09-10 弗·哈夫曼-拉罗切有限公司 作为5-ht6、5-ht24的苯并咪唑衍生物
SI22127A (sl) * 2005-10-07 2007-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo kandesartan cileksetila
CZ299265B6 (cs) * 2005-10-20 2008-05-28 Zentiva, A. S. Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN100344625C (zh) * 2005-12-22 2007-10-24 浙江天宇药业有限公司 一种制备坎地沙坦的方法
US7943780B2 (en) * 2006-02-15 2011-05-17 Matrix Laboratories Ltd. Process for the preparation of candesartan cilexetil
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
WO2008035360A2 (fr) * 2006-06-13 2008-03-27 Alembic Limited Nouvelles formes cristallines
EP2049510A1 (fr) * 2006-07-28 2009-04-22 Krka Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation de la forme i du candésartan cilexétil
CN102813635A (zh) 2006-08-10 2012-12-12 武田药品工业株式会社 药物组合物
CA2665226C (fr) 2006-10-05 2014-05-13 Santarus, Inc. Nouvelles formulations pour une liberation immediate d'inhibiteurs de pompe a protons et procedes d'utilisation de ces formulations
EP1908469A1 (fr) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Antagonistes du récepteur de l'angiotensine II pour traiter des désordres sistémiques des chats
US8143435B2 (en) * 2006-10-10 2012-03-27 Mylan Laboratories Ltd. One pot process for the preparation of candesartan
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
EP2103610B1 (fr) 2006-12-06 2011-09-21 Shanghai Allist Pharmaceutical., Inc. Sels de dérivés d'acide imidazol-5-carboxylique, procédés de préparation et utilisation
CN101214242A (zh) 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
EP1952806A1 (fr) 2007-02-01 2008-08-06 Helm AG Procédé de préparation des produits d'absorption de candesartan
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
JP4866901B2 (ja) 2007-02-07 2012-02-01 協和発酵キリン株式会社 ３環系化合物
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
PT2019668E (pt) * 2007-03-08 2010-11-11 Teva Pharma Composição farmacêutica compreendendo candesartan cilexetil
TWI415634B (zh) * 2007-03-28 2013-11-21 Takeda Pharmaceutical 固態醫藥組成物
WO2008128985A1 (fr) 2007-04-18 2008-10-30 Probiodrug Ag Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
SI22488A (sl) * 2007-04-24 2008-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalni 1-(cikloheksiloksikarboniloksi)etil 1-((2'-cianobifenil-4-il)metil) - 2-etoksi-1h-benz(d)imidazol -7-karboksilat in proces za njegovo pripravo
RU2009141539A (ru) 2007-04-25 2011-05-27 Тева Фармасьютикал Индастриес Лтд. (Il) Комплекс фармацевтического наполнителя
WO2008151257A2 (fr) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
EP2170868A1 (fr) * 2007-07-11 2010-04-07 Alembic Limited Procédé amélioré pour la préparation de candésartan cilexétil
JP2010538071A (ja) * 2007-09-07 2010-12-09 セラヴァンス， インコーポレーテッド 二重作用性降圧剤
EP2225210B1 (fr) * 2007-12-11 2012-04-25 Theravance, Inc. Dérivés de benzimidazole à double effet et leur utilisation en tant qu'antihypertenseurs
JP2011512416A (ja) 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
JP2011518884A (ja) 2008-04-29 2011-06-30 セラヴァンス， インコーポレーテッド 二重活性抗高血圧剤
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US20100210853A1 (en) * 2008-06-24 2010-08-19 Hetero Research Foundation Process for preparation of candesartan cilexetil
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US7863309B2 (en) 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
CN101648918B (zh) * 2008-08-15 2013-01-09 联化科技股份有限公司 坎地沙坦酯的中间体化合物及其合成方法
EP2165702B1 (fr) 2008-09-17 2011-11-16 Helm AG Compositions dissoutes facilement et stables de candesartan cilexetil préparé avec une granulation par voie humide
EA201170549A1 (ru) * 2008-10-10 2012-01-30 Янссен Фармацевтика Нв Комбинированная терапия с использованием блокаторов рецепторов ангиотензина и антагонистов рецепторов вазопрессина
KR100995755B1 (ko) 2008-10-31 2010-11-19 일동제약주식회사 트리틸 칸데사르탄 실렉세틸의 개선된 제조방법
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
WO2010075347A2 (fr) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Méthode de traitement de l'hypertension avec au moins un agent bloquant les récepteurs d'angiotensine ii et de la chlorthalidone
WO2010093601A1 (fr) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
US7956054B2 (en) 2009-07-07 2011-06-07 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
EP2456762B1 (fr) 2009-07-22 2013-10-16 Theravance, Inc. Agents antihypertenseurs à double action à base d'oxazole
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
WO2011080684A1 (fr) 2009-12-31 2011-07-07 Ranbaxy Laboratories Limited Procede de preparation de candesartan cilexetil
WO2011090929A1 (fr) 2010-01-19 2011-07-28 Theravance, Inc. Agents antihypertenseurs de thiophène, pyrrole, thiazole et furane à double action
WO2011092666A1 (fr) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Procede ameliore de preparation de candesartan cilexetil, formes polymorphes de n-trityl candesartan et leurs utilisations
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
CN101880241B (zh) * 2010-07-14 2013-04-17 浙江美诺华药物化学有限公司 一锅法制备2-(取代苯基)甲氨基-3-硝基苯甲酸甲酯的方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR101251741B1 (ko) * 2010-12-16 2013-04-05 동화약품주식회사 칸데사르탄실렉세틸의 개선된 제조방법
EP2686313B1 (fr) 2011-03-16 2016-02-03 Probiodrug AG Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
CN102198129B (zh) * 2011-03-22 2016-03-30 浙江华海药业股份有限公司 含有坎地沙坦酯和氢氯噻嗪的口服片剂
CN102206186A (zh) * 2011-04-18 2011-10-05 张家港市信谊化工有限公司 坎地沙坦环合物的制备方法
KR101708538B1 (ko) 2011-08-26 2017-02-20 욱크하르트 리미티드 심혈관 질환의 치료 방법
WO2013041944A1 (fr) 2011-09-19 2013-03-28 Ranbaxy Laboratories Limited Procédé pour la préparation de candésartan cilexétil micronisé
JP5850697B2 (ja) * 2011-10-18 2016-02-03 株式会社トクヤマ カンデサルタンシレキセチルの製造方法
BR112014014527A2 (pt) 2011-12-15 2017-06-13 Takeda Pharmaceuticals Usa Inc combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
CN102391254B (zh) * 2011-12-16 2013-03-13 珠海润都制药股份有限公司 一种坎地沙坦的制备方法
CN103304543A (zh) * 2012-03-12 2013-09-18 邓俐丽 一种坎地沙坦酯的制备方法
CN102633816A (zh) * 2012-03-30 2012-08-15 李莎 头孢西丁酯化前体药物化合物及口服制剂
CA3095012C (fr) 2012-05-01 2023-02-07 Translatum Medicus Inc. Procede de traitement et de diagnostic de maladies menant a la cecite
WO2013167453A1 (fr) 2012-05-07 2013-11-14 Bayer Pharma Aktiengesellschaft Procédé pour fabriquer une forme pharmaceutique comprenant de la nifédipine et du candésartan cilexétil
US20140134187A1 (en) 2012-06-25 2014-05-15 The Johns Hopkins University Therapeutic and diagnostic methods for autism spectrum disorders and other conditions
WO2014054798A1 (fr) 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター Médicament destiné à inhiber une métastase de tumeur maligne
CN102952040A (zh) * 2012-11-20 2013-03-06 峨眉山天梁星制药有限公司 一种坎地沙坦酯中间体的硝基还原为氨基的方法
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
EP2968439A2 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
JP6422868B2 (ja) 2013-07-23 2018-11-14 第一三共株式会社 高血圧症の予防又は治療のための医薬
CN104098550A (zh) * 2014-07-17 2014-10-15 浙江华海药业股份有限公司 一种精制三苯甲基坎地沙坦的方法
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
WO2016192099A1 (fr) * 2015-06-05 2016-12-08 浙江华海药业股份有限公司 Procédé de préparation de trityl candésartan
CZ2015687A3 (cs) 2015-10-02 2017-04-12 Zentiva, K.S. Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu
EP3219309A1 (fr) 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Compositions pharmaceutiques comprenant combinaisons à dose fixe de amlodipine, de candesartan cilexetil et de hydrochlorothiazide pour le traitement de l'hypertension
EP3434284A4 (fr) 2016-03-24 2019-11-13 Daiichi Sankyo Company, Limited Médicament pour le traitement d'une maladie rénale
CN106432201B (zh) * 2016-09-14 2019-04-23 威海迪素制药有限公司 一种坎地沙坦酯结晶的制备方法
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
KR20210009315A (ko) 2018-04-11 2021-01-26 오하이오 스테이트 이노베이션 파운데이션 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물
US20220089526A1 (en) 2019-01-02 2022-03-24 Linhai Huanan Chemical Co., Ltd. Synthesis Method for Candesartan Cilexetil Intermediate
WO2020150473A2 (fr) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP3996709A1 (fr) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan pour le traitement de l'hypertension chez les chiens
CN110514758A (zh) * 2019-08-21 2019-11-29 天地恒一制药股份有限公司 一种坎地沙坦酯有关物质的检测方法
WO2022033202A1 (fr) * 2020-08-13 2022-02-17 南京海融医药科技股份有限公司 Promédicament d'ester d'ibuprofène, composition pharmaceutique et procédé de préparation et d'utilisation
US11655220B2 (en) 2020-10-22 2023-05-23 Hetero Labs Limited Process for the preparation of angiotensin II receptor blockers
EP4052695A1 (fr) 2021-03-05 2022-09-07 Midas Pharma GmbH Compositions pharmaceutiques orales stables à libération immédiate à dose fixe comprenant de l'amlodipine, de l'atorvastatine et du candésartan cilexétil
EP4370101A1 (fr) 2021-07-15 2024-05-22 Adamed Pharma S.A. Composition pharmaceutique comprenant de l'amlodipine, du candésartan cilexetil et de l'hydrochlorothiazide pour le traitement de l'hypertension
CN114149414B (zh) * 2021-12-23 2023-08-04 浙江永宁药业股份有限公司 一种利用微反应器连续流制备坎地沙坦的方法
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制
EP4374855A1 (fr) 2022-11-22 2024-05-29 KRKA, D.D., Novo Mesto Forme pharmaceutique de dosage de candesartan et d'indapamide
CN121175053A (zh) 2023-05-24 2025-12-19 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防
TW202541793A (zh) 2023-12-15 2025-11-01 德商百靈佳殷格翰維美迪加股份有限公司 用於預防貓之全身性疾病之血管緊張素ii受體拮抗劑

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
US4775679A (en) * 1985-04-25 1988-10-04 Merck & Co., Inc. Certain heterocyclic-ethyl-2,3-dihydrobenzofurans useful as anti-inflammatory agents
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (fr) * 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4764623A (en) * 1987-06-15 1988-08-16 American Home Products Corporation N-(1H-tetrazol-5-yl-alkylphenyl)polyfluoroalkanamides
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0400835A1 (fr) * 1989-05-15 1990-12-05 Merck & Co. Inc. Benzimidazoles substitués comme antagoniste d'angiotensine II
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5250554A (en) * 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof

Also Published As

Publication number Publication date
HU911347D0 (en) 1991-10-28
EP0459136A1 (fr) 1991-12-04
NL970044I1 (nl) 1998-03-02
KR100200541B1 (ko) 1999-06-15
DE69123784T2 (de) 1997-04-17
EP0720982B1 (fr) 2002-11-13
FI911936A0 (fi) 1991-04-22
CN1147515A (zh) 1997-04-16
FI982761L (fi) 1998-12-21
US5401764A (en) 1995-03-28
AU647469B2 (en) 1994-03-24
HK1000803A1 (en) 1998-05-01
NO970195D0 (no) 1997-01-16
CY2150B1 (en) 2002-08-23
JPH0899960A (ja) 1996-04-16
LV10258A (lv) 1994-10-20
EP0720982A1 (fr) 1996-07-10
NO300923B1 (no) 1997-08-18
NO970195L (no) 1997-01-16
NL970044I2 (nl) 1998-06-02
JP2514282B2 (ja) 1996-07-10
LV10258B (en) 1995-04-20
DK0720982T3 (da) 2003-03-17
NO1998018I1 (no) 1998-06-25
US5196444A (en) 1993-03-23
DE69133149T2 (de) 2003-03-13
FI911936A7 (fi) 1991-10-28
ATE227709T1 (de) 2002-11-15
CN1058966C (zh) 2000-11-29
PT97451A (pt) 1992-01-31
DE19875004I2 (de) 2002-03-28
FI108434B (fi) 2002-01-31
US5328919A (en) 1994-07-12
NZ237949A (en) 1995-07-26
ES2181742T3 (es) 2003-03-01
NO302752B1 (no) 1998-04-20
DK0459136T3 (da) 1997-04-01
ATE146779T1 (de) 1997-01-15
GR3022172T3 (en) 1997-03-31
KR910018359A (ko) 1991-11-30
CA2204290A1 (fr) 1991-10-28
PT97451B (pt) 1997-01-31
FI114983B (fi) 2005-02-15
EP0459136B1 (fr) 1996-12-27
CN1055927A (zh) 1991-11-06
AU7533191A (en) 1991-11-21
CA2040955A1 (fr) 1991-10-28
ES2095266T3 (es) 1997-02-16
CN1048486C (zh) 2000-01-19
NO911586L (no) 1991-10-28
CA2040955C (fr) 1998-02-03
DE69123784D1 (de) 1997-02-06
HU210871A9 (en) 1995-08-28
FI982761A0 (fi) 1998-12-21
CA2204290C (fr) 2001-12-18
JPH04364171A (ja) 1992-12-16
NO911586D0 (no) 1991-04-22
JP2853611B2 (ja) 1999-02-03
HUT57736A (en) 1991-12-30
HU213266B (en) 1997-04-28
IE911317A1 (en) 1991-11-06
US5705517A (en) 1998-01-06
DE69133149D1 (de) 2002-12-19

Similar Documents

Publication Publication Date Title
NO1998018I1 (no) Candesartan
CA2400124A1 (fr) Inhibiteurs de tnf-.alpha.
KR940005617A (ko) 안지오텐신 ii길항 물질
CA2229000A1 (fr) Derives de 1-biphenylimidazole, leur preparation et leur utilisation therapeutique
TR200201752T2 (tr) Dipeptid nitril katepsin K inhibitörleri.
DE10299029I1 (de) Benzimidazole diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE146076T1 (de) Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
CA2436361A1 (fr) Compose antagoniste de l'angiotensine ii pour utilisation comme analgesique et anti-inflammatoire
KR930701415A (ko) 약학적으로 활성인 벤조퀴나졸린 화합물
CA2420055A1 (fr) Agent de reduction du fibrinogene
DE59408213D1 (de) Pyrrolidin- und oxazolidin derivate , ihre herstellung und ihre verwendung als thrombocyten-aggregations-hemmer
ES2184892T3 (es) Antagonistas del receptor at1 para prevenir y tratar la insuficiencia renal postisquemica y para proteger los riñones isquemicos.
NO20002655L (no) 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet
RU2001132073A (ru) Фармацевтическая композиция для предотвращения, лечения или ингибирования развития простой ретинопатии и препролиферирующей ретинопатии
AU615385B2 (en) Heterocyclicgaunidines as 5ht antagonists
NZ309499A (en) Styryl benzimidazole derivatives useful as inhibitors of smooth muscle cell proliferation
FI3947360T3 (fi) Serotoniini 5-ht2b:tä estäviä yhdisteitä
RU2007143054A (ru) Терапевтическое средство против кератоконъюнктивального расстройства
KR930700455A (ko) 치환된 벤즈이미다졸